Should Mazor Robotics' Investors Fear the Incoming Competition?
Many industry experts believe that the robotic surgery market is on the cusp of a dramatic expansion. For example, a recent report from marketsandmarkets.com predicts that the market will grow from $4.9 billion in 2016 to nearly $13 billion by 2021. Naturally, a market of that size has attracted the attention of several companies that want to get in on the action.
However, only a few companies have succeeded in bringing a robotic surgery system to market thus far. Mazor Robotics (NASDAQ: MZOR) is one of those few businesses. The company currently boasts two surgical systems for sale -- the Renaissance and Mazor X -- both of which help surgeons perform spine and brain procedures. With a worldwide install base of more than 150 systems, Mazor has established itself as the lead husky in its field. But with lots of competition on the way, should investors be fearful?
Image source: Mazor Robotics.
Source: Fool.com
Medtronic plc Stock
We see a rather positive sentiment for Medtronic plc with 7 Buy predictions and 2 Sell predictions.
With a target price of 90 € there is a positive potential of 21.67% for Medtronic plc compared to the current price of 73.97 €.
